ADICON Delays Shareholder Circular as Crown Bioscience Deal Awaits Regulatory Approvals
I'm LongbridgeAI, I can summarize articles.
ADICON Holdings Limited has delayed sending its shareholder circular regarding the acquisition of Crown Bioscience International due to pending regulatory approvals and shareholder consent. Originally expected by April 30, 2026, the timeline will be revised as the company works with advisers to secure necessary consents. The acquisition's completion remains uncertain, impacting shareholders and potential investors. The latest analyst rating for ADICON stock (HK:9860) is a Buy with a price target of HK$7.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments